Fluence Energy shares surged nearly 9% in pre-market trading on Tuesday after UBS reversed its long-held bearish stance on the energy storage company, upgrading the stock to Neutral from Sell and raising its price target to $12 from $9.
The move, led by UBS analyst Jon Windham, marks a significant shift for one of the most consistently negative voices on Fluence Energy (FLNC). The bank argued that the company’s recent cut to its fiscal 2026 guidance likely establishes a floor for near-term earnings expectations, creating what Windham described as a “favorable benchmark” for accelerated earnings growth in fiscal 2027.
UBS now projects Fluence will grow revenue at a 22% compound annual rate through 2030, driven by expanding demand for battery energy storage systems, particularly in hybrid solar-plus-storage installations. The bank also revised its adjusted EBITDA forecasts for fiscal 2026 through 2028, concluding that some revenue previously expected in the current fiscal year had been pushed into the following year rather than lost entirely.
This distinction is crucial for investors trying to determine whether the company’s disappointing third-quarter results represented a temporary timing issue or a deeper structural problem. The market appeared to embrace the former interpretation, with shares climbing to the $11 to $12 range in pre-market activity—already approaching UBS’s newly established target.
The rally follows a brutal stretch for the stock. Earlier this month, Fluence reported a third-quarter adjusted loss of 24 cents per share, far worse than the 2-cent loss analysts had expected. Revenue from continuing operations came in at $600.2 million, well below the consensus estimate of $848.2 million. The company subsequently slashed its fiscal 2026 revenue outlook to a range of $2.9 billion to $3.1 billion, down from its prior forecast of $3.2 billion to $3.6 billion and below the analyst consensus of $3.35 billion.
Those results triggered a wave of negative analyst actions. Morgan Stanley, Roth Capital, and Citigroup all reduced their price targets following the report, while GLJ Research downgraded the stock to Hold with a $12.89 target on August 20. Citigroup maintained its Buy rating but cut its target to $20 on August 14.
Despite Tuesday’s bounce, the stock remains deeply depressed. Fluence touched a 52-week low of $6.60 earlier this year, a dramatic fall from its peak of $33.51. The shares continue to trade below key moving averages, sitting 12.7% under the 20-day simple moving average of $12.84 and 28.8% below the 50-day SMA of $15.75. The longer-term picture is even more challenging, with the stock trading 39.1% below its 200-day SMA of $18.40.
Technical indicators remain bearish. A death cross formed in August when the 50-day SMA crossed below the 200-day SMA, a pattern that typically signals continued downward pressure. MACD momentum also remains negative, suggesting rallies may struggle to sustain themselves unless buyers can establish more persistent control.
Broader market conditions provided some support on Tuesday, with the S&P 500 advancing 0.4% and the Nasdaq climbing 0.8%. However, analysts noted that an 8.7% move cannot be attributed to general market strength alone—the UBS upgrade was clearly the primary catalyst.
Fluence’s heavy weighting in several specialized ETFs means its stock movements can be amplified by fund flows. The Corgi Battery Energy Storage Systems ETF (WATS) holds a 4.10% position, the Trenchless Fund ETF (RVER) carries a 6.99% weighting, and the Moonvest ETF (MNVT) maintains a 4.98% allocation. Significant inflows or outflows from these funds can force automatic buying or selling of Fluence shares.
While the UBS upgrade removes a significant overhang, the bank’s decision to stop short of a Buy rating reflects lingering caution. Fluence still faces execution challenges, and with the stock already trading near the new $12 target, the easy gains from this re-rating may already be priced in. The average analyst price target across all coverage stands at $17.10, suggesting some on Wall Street see further upside if the company can deliver on its fiscal 2027 recovery narrative.